top of page

Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access

Feb 18, 2022

  • Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4

  • Cost savings from Lenalidomide Sandoz can expand treatment options for patients with haemato-oncology conditions1,2

  • Sandoz is committed to developing and providing generic oncology therapies, to provide patients access to affordable, high-quality medicines

Basel, February 18, 2022 — Sandoz today announced the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as recommended by the latest European Society for Medical Oncology (ESMO) guidelines. The medicine will become available to patients in 19 countries across Europe.

“We are proud to make life-enhancing cancer treatments more accessible by launching our affordable and effective Sandoz Lenalidomide”, said Rebecca Guntern, Head of Sandoz Europe.

She added: “Sandoz is committed to developing and providing generic oncology therapies, to increase patient access to affordable, high-quality medicines. Today, we offer a broad portfolio of more than 50 oncology products3, ranging from biologics to chemotherapeutics, hormones and supportive care treatments, covering a wide range of cancer indications."

The cost of treating multiple myeloma patients is high and continues to rise5. Affordability of and access to new multiple myeloma treatments pose a major challenge around the world6. Cost savings from Lenalidomide Sandoz promise to expand access to treatment options for multiple myeloma patients1,2. Similar to multiple myeloma patients, cost savings from Lenalidomide Sandoz will benefit previously treated follicular lymphoma patients, adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality, and relapsed or refractory mantle cell lymphoma patients1.

Sandoz is the #1 provider of generic oncology medicines in Europe7 with a growing portfolio that covers an industry-leading 75% of molecules on the WHO's global Oncology Essential Medicines List8,9. Sandoz invests in development to improve the lives of cancer patients and free up healthcare resources through increased access to high-quality, affordable medicines.

About Lenalidomide

Lenalidomide is an oral thalidomide analogue with immunomodulatory, antiangiogenic, and antineoplastic properties used for the treatment of various haemato-oncology conditions [1]. Lenalidomide is recommended by the latest ESMO guidelines [4]. It is available only through special distribution program because of its serious side effects, including possible birth defects or death of an unborn baby [1]. Lenalidomide is available as hard capsules and need to be taken exactly as prescribed [1].



bottom of page